Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psilocybin
Biotech
Compass' psychedelic therapy wins ph. 3, investors unimpressed
Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression.
James Waldron
Jun 23, 2025 8:05am
Psyence walks away from acquisition of fellow psilocybin biotech
Oct 7, 2024 5:16am
Psyence acquires fellow psilocybin biotech Clairvoyant
Sep 6, 2024 9:25am
Compass tracks PTSD improvements in midphase psilocybin trial
May 8, 2024 8:07am
Reunion nets $103M, one of the largest for a psychedelic biotech
May 2, 2024 6:30am
Compass, Hackensack Meridian ink research deal for psilocybin
Jan 17, 2024 10:53am
